Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) operates as a diversified healthcare and biomedicine company primarily engaged in pharmaceutical production and sales, alongside personal care products, elderly care services, commercial concrete, and other segments in China. Founded in 1999 and headquartered at Pengrun Building, No. 26 Xiaoyun Road, Beijing, China, the company offers a broad portfolio of pharmaceutical products including Anemarrhena saponin BII and capsules for vascular dementia; Naloxone Hydrochloride injection and Naltrexone Hydrochloride tablets for opioid-related treatments and ethanol poisoning relief; pain management solutions such as Hydrocodone acetaminophen tablets, Tramadol Hydrochloride injections and tablets, Oxycodone Hydrochloride injection and sustained-release tablets (40mg), and Aminophenol Tramadol tablets; respiratory and antiemetic therapies like Ambroxol Hydrochloride injection and Tropisetron Mesylate injection; cardiovascular medications including Metoprolol succinate API, Bisoprolol Fumarate tablets, Bisoprolol amlodipine tablets, and Benidipine Hydrochloride tablets; gout treatment with Febuxostat tablets; diabetes control via Glipizide Dispersible tablets; antifungal agents such as Bifonazole API and cream; cognitive enhancers like Huperzine A tablets; women's health products including Wujia Biochemical capsules and Clindamycin phosphate vaginal gel; probiotics such as Lactobacillus tablets; motion sickness prevention with Phencynonate Hydrochloride tablets; and additional items like Cediodine lozenges for pharyngitis, Piracetam injections, and Bromazepine Hydrochloride injections. In July 2024, the company adjusted its global strategy to focus on becoming a leading medical and health industry service provider, emphasizing CNI biomedicine, health products, nursing medical services, and commercial concrete; it signed a global strategic cooperation agreement with Hailai Technology in September 2024 to advance these objectives. Beijing Centergate Technologies maintains operations predominantly in China, with international reach in pharmaceuticals, employs approximately 2,267 people, and reports biomedicine as its largest revenue segment, followed by commercial concrete and elderly care.